PofoliaShared via Pofolia

Cartilage· 2026Q1

Sequential Exposure to Acute, Intermediate, and Late Synovial Fluid Fracture Hematoma after Ankle Fracture Promotes Cartilage Damage in Vitro Partially Attenuated by Anti Inflammatory Agents

Evan Fedock, Nicholas B. Allen, Alexandra Hunter Aitchison, Will Sharp et al.

Short summary

Sequential exposure to synovial fluid fracture hematoma (SFFH) from ankle fractures in vitro promoted cartilage degradation, with anti-inflammatory agents (IL-1Ra, dexamethasone, doxycycline) reducing inflammatory cytokines and MMPs but not preventing elevated cartilage matrix degradation markers or improving histological preservation.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Sequential exposure to SFFH in vitro increased pro-inflammatory cytokines, MMPs, and cartilage breakdown products.
  • Anti-inflammatory agents (IL-1Ra, dexamethasone, doxycycline) reduced inflammatory cytokines and MMP levels in cultured cartilage.
  • Despite reduced inflammation, cartilage matrix degradation markers (CTX-II, sGAGs) remained elevated, and histological preservation was not significantly improved.
  • Chondrocyte survival was not significantly different among the tested groups.

AI-generated from the title and abstract; the full text is not read.

Abstract

Background Post-traumatic osteoarthritis (PTOA) following intra-articular fractures (IAFs) remains a common sequela after injury. Cartilage degeneration after injury is influenced by multiple factors, including elevated proinflammatory cytokines produced by synovial fluid fracture hematoma (SFFH). Targeting this inflammatory response may reduce cartilage damage. This study evaluated cartilage injury and inflammatory mediator changes caused by SFFH, assessing whether commercially available anti-inflammatory agents can suppress the inflammatory cascade implicated in PTOA and reduce chondrocyte death. Methods Ankle synovial fluid was collected from 54 patients with IAFs. Human cartilage discs harvested from talar allografts were cultured in standard chondrocyte media (SCM) and initial media was collected. Explants were randomized into five groups: (1) control (SCM only), (2) sequential exposure SFFH representing acute (days 0–2), intermediate (days 3–9), and late (≥10) phases, (3) Group 2 with interleukin-1 receptor antagonist (IL-1Ra), (4) Group 2 with dexamethasone, and (5) Group 2 with doxycycline. After exposure, spent media was collected. Samples were analyzed for cytokines, matrix metalloproteinases (MMPs), C-terminal telopeptides of type II collagen (CTX-II), and sulfated glycosaminoglycans (sGAGs), with histological assessment performed to evaluate viability and proteoglycan content. Results SFFH exposed cartilage showed increased levels of proinflammatory cytokines, MMPs, and cartilage breakdown products compared to controls. Treatment with IL-1Ra, dexamethasone, or doxycycline all reduced inflammatory cytokines and MMP levels. Safranin O staining, indicating proteoglycan content, was lowest in group 2. No significant difference in chondrocyte survival was observed among groups. Conclusion Sequential exposure to SFFH creates a sustained proinflammatory and catabolic environment that promotes biochemical cartilage degradation. IL-1Ra, dexamethasone, and doxycycline reduced inflammatory cytokine and MMP concentrations while cartilage matrix degradation markers remained elevated and histologic preservation was not significantly improved. These findings suggest that suppression of inflammatory pathways alone may be insufficient to fully prevent cartilage injury under cumulative SFFH exposure. Clinical Relevance Acute anti-inflammatory therapy following IAF may modulate inflammatory and catabolic mediator production within the post-fracture joint environment. Further in vivo investigation is required to determine whether these biological effects translate into durable cartilage preservation or altered PTOA risk. Level of Evidence Laboratory study.

The authors' abstract, as published at the source. Cartilage, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Rheumatology

RheumatologyMedicine